ArticleBMJ open2026
Strategic analysis of electronic prescriptions in Iran: a qualitative study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to examine the electronic prescription programme in Iran by thoroughly identifying the key strengths, weaknesses, opportunities and threats (SWOT) associated with its implementation and utilisation among healthcare stakeholders.
designA thematic analysis was adopted, with data systematically examined through the SWOT analytical framework.
settingHospital, pharmacy, specialised clinic, insurance affiliated clinic in Iran.
participantsParticipants consisted of four groups involved in implementing the electronic prescription programme, including physicians, pharmacists, nurses and hospital administrative employees. Moreover, research participants were selected using a purposive sampling approach and sampling continued until data saturation was reached.
methodsSemistructured interviews were employed for data collection. The data analysis steps were systematically executed using Braun and Clarke's six-phase thematic analysis approach. Within the study's conceptual framework based on SWOT analysis, themes and codes were categorised into positive (strengths, opportunities) and negative (weaknesses, threats) drivers. In addition, the method proposed by Lincoln and Guba was employed to endorse the data credibility.
resultsOverall, data saturation was reached with 25 participants and two major themes and four minor themes. The 'strengths' theme comprised patient safety, economic efficiency, information sharing, remote access and drug list accessibility. The 'weaknesses' theme encompassed internet and electricity dependency, resistance to implementation, numerous platforms and diverse insurer schemes and frequent changes in insurance company tariffs. The 'opportunities' theme consisted of health system networking, clarifying processes, eliminating drug intermediaries, improving health service quality, enhancing data banks, expediting drug monitoring and improving technological infrastructures in the health field. Ultimately, the 'threats' theme involved confidential information access and misuse, damaged drug barcodes, incorrect data recording, patient dissatisfaction and government financial burden.
conclusionsDue to the fact that the challenges and benefits associated with this system vary across countries depending on their technical and non-technical capacities and infrastructures, the findings of the current research can contribute to promoting the system within our country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.